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AbstrAct:
Resistance of Human Immunodeficiency Virus (HIV) to antiretroviral drugs is an important 
limitation in achieving complete suppression of viral replication and therefore represents an 
important clinical issue. It refers especially to therapy-naive individuals infected with resistant 
HIV strains, e.g. individuals with transmitted drug resistance (TDR). Transmitted drug resistance 
mutations (TDRMs) are clinically relevant and may reduce the efficacy of antiretroviral therapy. In 
this paper, we report the first case of HIV-1 transmitted triple-class drug resistance in Croatia. The 
aim of this study was to characterize drug resistance patterns and TDRMs in the newly diagnosed, 
treatment-naive HIV-1 patient with such a complex resistance pattern. Sanger sequencing (SS) of 
the sample showed four reverse transcriptase inhibitor (RTI) resistance mutations (E44D, T215E, 
K103N, L100I) affecting two drug classes and two protease inhibitor resistance mutations (V32I, 
I47V). To characterize HIV-1 minority drug resistance variants below the detection limit of SS, 
deep sequencing (DS) analysis was performed. DS analysis identified the same triple class resis-
tance pattern that was identified by SS with addition of several other RTI mutations. The patient 
described in this report is the first patient with HIV-1 triple-class resistance in Croatia and further 
studies will be directed toward analysing possible local onward transmission of this resistant virus. 
Keywords: HIV; Transmitted drug resistance  (TDR); Sanger sequencing (SS); Deep sequencing 
(DS)
Sažetak:
Rezistencija HiV1 ViRusa na 3 klase lijekoVa: pRVi slučaj
Rezistencija virusa humane imunodeficijencije (HIV) na antiretrovirusne lijekove sprječava 
supresiju virusne replikacije te predstavlja značajan izazov u kliničkoj medicini. Posebno valja 
istaknuti problem primarne rezistencije (engl. transmitted drug resistance, TDR) koja se odnosi na 
prethodno neliječene osobe koje su zaražene rezistentnim sojevima HIV-a. Mutacije koje su pov-
ezane s primarnom rezistencijom (engl. transmitted drug resistant mutations, TDRM) su klinički 
značajne i mogu nepovoljno djelovati na učinkovitost antiretrovirusnog liječenja. U ovom je radu 
opisana prva osoba s primarnom rezistencijom HIV-a na 3 klase antiretrovirusnih lijekova u Hr-
vatskoj. Cilj ovog istraživanja bio je analizirati obrasce primarne rezistencije i TDRM u novodi-
jagnosticiranog i neliječenog HIV-om zaraženog pojedinca. Primjenom Sangerovog sekvenciranja 
(SS) dokazali smo četiri mutacije povezane s rezistencijom na inhibitore reverzne transkriptaze 
(E44D, T215E, K103N, L100I) koje smanjuju osjetljivost na dvije klase lijekova (nukleozidne 
analoge inhibitore reverzne transkriptaze i nenukleozidne inhibitore reverzne transkriptaze) kao i 
dvije mutacije (V32I, I47V) povezane s rezistencijom na inhibitore proteaze. U svrhu identifikacije 
mogućeg postojanja manjinskih rezistentnih varijante ispod granice detekcije SS-a, provedena je 
analiza dubinskim sekvenciranjem (DS). DS analiza identificirala je isti obrazac rezistencije na 3 
klase antiretrovirusnih lijekova identificiran s SS uz nekoliko dodatnih mutacija. U ovom je radu 
opisan prvi slučaj primarne rezistencije HIV-a na 3 klase antiretrovirusnih lijekova, a buduća 
istraživanja analizirat će moguće putove transmisije ovog rezistentnog virusa u Hrvatskoj. 
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introduction
Highly active antiretroviral therapy (HAART) has had a tremendous 
impact on many individuals infected with Human Immunodeficiency 
Virus (HIV) and is the most important achievement in the history of 
HIV-therapy so far1. 
Despite the wide use and benefit of antiretroviral drugs, the efficacy of 
HAART can be compromised by the emergence of drug resistance2.
Resistance occurs as a result of mutations in the pol region of HIV 
genome coding for viral enzymes, reverse transcriptase, protease and 
integrase, that represent molecular targets of antiretroviral drugs3. 
Resistance of HIV to antiretroviral drugs is an important limitation 
to the suppression of viral replication and therefore represents an 
important clinical issue4. This issue refers especially to therapy-naive 
individuals infected with resistant HIV strains (transmitted drug re-
sistance, TDR). Transmitted-drug resistance mutations (TDRMs) can 
persist significantly longer than acquired DRMs in infected persons, 
even in the absence of drug pressure5. That goes in favor of hypothesis 
that TDR is driven mainly by onward transmission from ART-naive 
individuals rather than from patients with a history of ART6-8. 
TDRMs may reduce the efficacy of antiretroviral therapy (ART), but 
genotypic resistance testing, performed before initiating treatment or 
after virologic failure, helps clinicians in choosing the right regimen 
and improves the efficacy of ART2.
To achieve the subsequent long-term treatment success, the resistance 
must be held under control by monitoring in both routine diagnostic 
setting and clinical research1,9.
Sanger sequencing has been the golden standard for characterization 
of HIV resistance so far, but with the development of new ˝deep 
sequencing˝ technologies and their increased sensitivity for detection 
of minor mutations, many clinical laboratories and research groups 
begun to implement it in their research10-14. With Sanger sequencing 
it is possible to detect viral quasispecies present in 15-20% of the total 
viral population while viral variants present in lower frequency will 
not be detected. On the other hand, deep sequencing allows analysis 
of viral minor variants represented in <1% of the total population, 
which provides a new insight on pathogenesis of HIV-1 infection. The 
advantages of such sequencing are of exceptional importance because 
deep sequencing can help monitor the resistance while minor resistant 
variants are still in development and do not dominated the viral popu-
lation10-14. The following groups of antiretroviral drugs are used for 
treatment of HIV-infection: nucleoside (NRTI) and non-nucleoside 
reverse transcriptase inhibitors (NNRTIs), protease inhibitors (PIs) 
and integrase inhibitors (INSTI). First-line ART consists of three or 
more antiretroviral drugs, usually two NRTIs in combination with 
one integrase inhibitor (recommended by the International AIDS 
Society-USA Guidelines, IAS-USA)2.
Croatia has a centralized system of care and universal free access to an-
tiretroviral drugs for all HIV infected persons15. HAART is available 
since 1998 while the resistance testing is performed since 200516.
In this paper we report the first sampled case of transmitted tri-




Viral RNA was isolated from patient plasma  using the QIAamp 
MinElute Virus Spin Kit (Qiagen, Hilden, Germany). HIV-1 geno-
typing was performed using an in-house HIV-1 genotyping assay with 
the BigDye Terminator v3.1 Cycle Sequencing Kit (Thermo Fisher 
Scientific, Dreieich, Germany) covering the protease (PR) and a part 
of reverse transcriptase (RT). Sequence analysis was performed on 
an ABI Prism 3500 capillary sequencer (Thermo Fisher Scientific, 
Germany). Vector NTI software (Thermo Fisher Scientific, Waltham, 
MA) was used to generate the consensus sequence and compare it 
with the reference strain HIV-1LAV-1 (GenBank number K02013). 
HIV-1 subtypes was assessed with the REGA HIV-1
subtyping tool Version 3.0.
Primary resistance to antiretroviral drugs was defined as the presence 
of ≥1 mutation placed on the WHO surveillance for drug resistance 
mutations (SDRM) list17. Clinically relevant resistance to Nucleoside 
Reverse Transcriptase Inhibitors (NRTI), Non-Nucleoside Reverse 
Transcripase Inhibitors (NNRTI) or Protease Inhibitors (PI) was eval-
uated with IAS Drug Resistance Mutation list and Stanford Univer-
sity HIV Drug Resistance Database (HIVdb), Genotypic Resistance 
Interpretation Algorithm version 8.82,18
In addition, drug  resistance result of HIVdb was compared to those 
of 2 other algorithms: Rega Institute and Agence Nationale de Re-
cherches sur le SIDA (ANRS).
Deep sequencing analysis
To characterize HIV-1 minority drug resistance variants present at 
frequencies (<10%) below the detection limit of Sanger sequencing, 
deep sequencing analysis was performed on the sample. The whole 
HIV-1 protease region and part of the reverse transcriptase region  
were sequenced with Illumina Miniseq (California, USA). After 
extraction, HIV-1 RNA was reverse transcribed with SuperScript® III 
First-Strand Synthesis System for RT-PCR (Invitrogen, Carlsbad, CA) 
and UNINEF primer55. Amplification of the target region was done 
in 4 separate multiplex PCR reactions using ALLinTM Taq DNA 
Polymerase (highQu GmbH, UK). Viral DNA libraries were prepared 
for deep sequencing with NEBNext® UltraTM II DNA Library Prep 
Kit for Illumina (New England BioLabs, MA, USA), according to the 
manufacturer’s instructions. Sequencing was performed using MiniS-
eq MID output 300 cycles reagent kit (paired-end; 150+150). The se-
quencing data were further analysed with HyDRA Web (Government 
of Canada, Ottawa, Canada) with a 5% sensitivity threshold19.
results
Patient characteristics
In 2017, a 26 year old man was diganosed with HIV at the chronic 
stage of infection. HIV-1 subtyping showed that the patient was 
infected with subtype B. The route of HIV-transmission was sex with 
men. The patient had no previous exposure to therapy. Viral load at 
the time of diagnosis was 27 400 HIV-1 RNA copies/ml of plasma.
Sanger sequencing (SS)
Sanger sequencing of the sample showed four RTI resistance mu-
tations (E44D, T215E, K103N, L100I) affecting two drug classes 
(NRTI, NNRTI)  and two PI resistance mutations (V32I, I47V) 
(Table 1).
When interpreting the results of genotipic resistance using three 
different algorithms, three levels of resistance were used: ˝S˝ (suscepti-
ble), ˝R˝ (resistant), and ˝I˝ (intermediate).
The results were considered consistent if all algorithms assigned the 
same level of resistance for the same drug. Complete divergence in 
the interpretation of the results was related to the case when one 
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algorithm assigned the ˝S˝  and the other ˝R˝ level for the same drug. 
The interpretation of the algorithms was considered to be partially 
divergent if both ˝S˝ and ˝I˝ or ˝R˝ and ˝I˝ levels of resistance were 
assigned for the same drug. Complete divergence in the interpre
tation of genotipic resistance results was observed for doravirine of 
NNRTI drug class and darunavir and fosamprenavir of PI. Compari-
son of genotipic resistance algorithms is displayed in Table 2. 
Deep sequencing (DS)
All mutation revealed by SS were also identified by deep sequencing. 
DS identified three additional  RTI mutations (K101E, T215S, 
N348I) (Table 3).
Mutation concordance between the two platforms was partial. DS 
analysis identified the triple class resistance with the same pattern that 
was identified by SS with addition of several other RTI mutations. 
diScuSion
The aim of this study was to characterize drug resistance patterns and 
TDRMs in the protease and reverse transcriptase-sequence of the 
first newly diagnosed/treatment naïve HIV-1 patient with triple class 
resistance from Croatia. Sanger sequencing identified triple class re-
sistance to three antiretroviral drug classes (NRTIs, NNRTs and PIs). 
Drug Class Mutations Resistance Interpretation
According to HIVdb
NRTI E44D, T215E LLR: AZT
NNRTI K103N, L100I R: EFV, NVP, RPV
IR: DOR, ETR
PI V32I, I47V IR: ATV/r, DRV/r, LPV/r
Table 1. Results of Sanger sequencing
NRTI- Nucleoside Reverse Transcriptase Inhibitors, NNRTI- Non-Nucleo-
side Reverse Transcripase Inhibitors, PI- Protease Inhibitors, AZT-zidovudine, 
EFV-efavirenz, NVP-nevirapine, RPV-rilpivirine, DOR-Doravirine, ETR-etra-
virine, ATV-atazanavir, DRV-darunavir, LPV-lopinavir, r-ritonavir, Mutation 







ABAKAVIR S S S
ZIDOVUDIN I R I
STAVUDIN I R I
DIDANOZIN S S S
EMTRICITABIN S S S
LAMIVUDIN S S S
TENOFOVIR S S S
NNRTI
DORAVIRIN I R S
EFAVIRENz R R R
ETRAVIRIN I S I
NEVIRAPIN R R R
RILPIVIRIN R R R
PI
ATAZANAVIR/r I S S




INDINAVIR/r I S S
LOPINAVIR/r S S S
SEKVINIIVIE/r S S S
TIPRANAVIR/r I S I








In addition to Sanger sequencing, the patient sample was also  
analyzed by deep sequencing. The aim was to compare the results of 
two platforms and to investigate the use and benefit of DS in routine 
diagnostic. 
HIV-1 infection in Croatia is primarily characterized by men who 
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have sex with men (MSM) who are mainly infected in Croatia20-21. 
Currently, HIV-infected persons are entering clinical care at early 
stages of infection (including acute and recent), but substantial pro-
portion of patients are still enrolled into clinical care at the symptom-
atic stage of HIV-disease (late presenters). The patient described in 
this paper classifies as a late presenter to clinical care. 
The prevalence of TDR in treatment-naive individuals remains stable 
in most developed countries and the prevalence of acquired drug 
resistance is decreasing22-29. This implies that further transmission of 
HIV-1 with TDRMs is occurring in ART-naive individuals6-8. 
The European SPREAD study, which included data for 25 European 
countries and Israel, showed an overall primary resistance prevalence 
of 8.4% (study period 2008 to 2010)30.
The prevalence of primary HIV resistance to RT inhibitors in Croatia 
was one of the highest in the world (22%) for the period 2006-
2008 and was associated with a local cluster of MSM caring SDRM 
T215S31. While NNRTI associated mutations were present at low 
frequency, no primary resistance mutations related to PI were found 
during this period31. Results of a more recent study focusing on the 
period 2014-2017, showed the emergence of SDRM to NNRTI and 
PI as well as high overall prevalence of primary resistance (around 
17%)32.
Besides T215 revertants (T215S being the most frequent)  that are 
found common in untreated persons in Croatia, recent data suggested 
that triple class resistance patterns also contribute to the spread of 
resistant strains in Croatia as well. Triple class resistant variants, sim-
ilar to those that have been described in the patient presented in this 
study, have been found to participate actively in the further spread of 
infection and primary resistance both locally and globally32. 
Results of DS analysis  partialy matched the results of  Sanger se-
quencing. In addition, DS identified low-abundant viral variants with 
frequencies <10% which were not detected by SS.
DS analysis showed that resistant variants responsible for initial 
infection could have gone under the radar of standard detection 
(<15%) in late-presenters diagnosed in chronic stage of infection. 
The implementation of new tehnologies with already existing ones is 
especially usefull  when dealing with complex clinical issues like this 
patient. This gives a new perspective and inside when choosing first-
line treatment options.
Availability of more antiretroviral drugs as well as new drug classes  
has led to virological success even in patients with resistance but indi-
viduals with triple class resistance have 
been associated with a higher risk of disease progression and death34-36. 
Therefore, the management of such patients is extremely challenging 
and the issue  raises public health concerns because the resistant virus 
is likely to be spread widely. Early diagnosis and antiretroviral treat-
ment of HIV-1 infections are therefore required to prevent the spread 
of drug-resistant HIV-1.
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Table 3. Comparison of SDRM detected with Sanger (SS) and deep sequencing (DS)
SDRM-Surveillance drug resistance mutations
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